Le Lézard
Classified in: Health, Science and technology
Subjects: Photo/Multimedia, Product/Service, Corporate Social Responsibility

Charles River Laboratories Announces Wind Contract with Repsol for European Operations


Charles River Laboratories International, Inc. (NYSE: CRL) today announced a wind energy contract with Repsol to address the entirety of the Company's European power requirements with renewable energy by 2023.

Charles River has entered into a virtual power purchase agreement (VPPA) with Repsol, a multi-energy company, for wind energy in Spain. The contract is for 30.5 megawatts (MW) of renewable energy, which is equivalent to avoiding carbon emissions from the annual electricity consumption of more than 28,000 homes.

The VPPA is associated with a wind farm that is part of Repsol's Delta II project. Repsol continues to promote its low carbon generation business through the development of quality and profitable renewable assets. The project has already begun construction and, once completed in 2023, will have a total capacity of 860 MW distributed among 26 wind farms located in the Spanish region of Aragon. Renewable power generation is one of the pillars of Repsol's decarbonization strategy. As a result, Repsol recently raised its installed capacity targets for 2030 to 20 gigawatts (GW), an increase of 60% over the previous target. By 2025, installed capacity will increase to 6 GW.

This VPPA is the second of Charles River's recent sustainability announcements related to renewable electricity?in June 2021, Charles River announced a solar contract to address the entirety of its North American electric power requirements. That project is also on track to begin providing Charles River with renewable energy benefits by 2023. As a result of the two VPPA's, Charles River anticipates that 90% of all its global electricity will be supplied by renewable energy by 2023.

Schneider Electric, the leading advisor on corporate renewable energy procurement globally, supported Charles River in the selection of and negotiations for the project. To learn more about Charles River's sustainability efforts visit its Corporate Citizenship page.

Approved Quotes

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.


These press releases may also interest you

at 16:25
Precision BioSciences, Inc. , an advanced gene editing company, today announced the anticipated return of three programs from Prevail Therapeutics Inc., a wholly owned subsidiary of Eli Lilly and Company. Precision exercised its option to regain...

at 16:25
AIDS Healthcare Foundation (AHF), the world's largest HIV/AIDS organization, is calling on public health officials to provide more education and prevention services around vaccinations as a new measles outbreak spreads through 17 U.S. states. As of...

at 16:19
Community research provider EmVenio Research and Prime Healthcare, an award-winning national health system, today announce their partnership to launch the EmVenio Research Center at Prime Healthcare. The partnership allows EmVenio to conduct research...

at 16:11
May 3rd to May 5th -- Get ready for a wave of fun and gratitude! Seventy-five amazing young international educators, therapists, nurses, and other care professionals are about to make a splash in San Clemente. These "Apex Care Professionals" are...

at 16:10
Exelixis, Inc. announced today that its first quarter 2024 financial results will be released on Tuesday, April 30, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss...

at 16:09
New research in the April 2024 issue of JNCCN?Journal of the National Comprehensive Cancer Network showcases the feasibility of...



News published on and distributed by: